Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact [Yahoo! Finance]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Yahoo! Finance
TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while reducing its price target from $68 to $64. The revision follows the company's recent 10-K report, with the firm adjusting its expense projections and updating share count estimates to account for pre-funded warrants currently outstanding. Last month, on March 25, Maze Therapeutics, Inc. (NASDAQ:MAZE) released its fourth-quarter and full-year 2025 results, outlining financial performance and key clinical developments. The company reported cash, cash equivalents, and marketable securities of $360.0 million as of December 31, 2025, compared to $196.8 million a year earlier, with funding expected to support operations into 2028. Research and development expenses totaled $27.6 million for the quarter and $108.4 million for the year, while general and administrative costs reached $10.5 million and $34.5 million, respectively. Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics Announces $150 Million Registered OfferingGlobeNewswire
- Maze Therapeutics (MAZE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holdMarketBeat
- Maze Therapeutics (MAZE) was given a new $64.00 price target by Truist Financial Corporation.MarketBeat
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]Yahoo! Finance
MAZE
Earnings
- 3/25/26 - Beat
MAZE
Sec Filings
- 4/22/26 - Form 8-K
- 4/22/26 - Form 424B5
- 4/2/26 - Form 4
- MAZE's page on the SEC website